DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,798 filers reported holding DANAHER CORPORATION in Q2 2021. The put-call ratio across all filers is 1.06 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,057,660 | -35.2% | 48,600 | -37.3% | 0.09% | -28.2% |
| Q2 2023 | $18,616,320 | -7.9% | 77,568 | -3.3% | 0.12% | 0.0% |
| Q1 2023 | $20,223,543 | +20.2% | 80,239 | +26.5% | 0.12% | +26.5% |
| Q4 2022 | $16,830,548 | +202.3% | 63,411 | +194.2% | 0.10% | +216.1% |
| Q3 2022 | $5,568,000 | -68.5% | 21,557 | -69.1% | 0.03% | -71.6% |
| Q2 2022 | $17,683,000 | +7088.2% | 69,749 | +8213.3% | 0.11% | +5350.0% |
| Q1 2022 | $246,000 | -91.7% | 839 | -90.7% | 0.00% | -92.9% |
| Q4 2021 | $2,961,000 | -83.5% | 9,000 | -84.7% | 0.03% | -87.6% |
| Q3 2021 | $17,900,000 | +200.1% | 58,795 | +164.5% | 0.23% | +237.3% |
| Q2 2021 | $5,965,000 | -18.3% | 22,226 | -31.4% | 0.07% | -28.0% |
| Q1 2021 | $7,297,000 | -82.7% | 32,419 | -82.9% | 0.09% | -84.0% |
| Q4 2020 | $42,151,000 | +1479.3% | 189,750 | +1431.1% | 0.58% | +1350.0% |
| Q3 2020 | $2,669,000 | +172.3% | 12,393 | +123.7% | 0.04% | +135.3% |
| Q2 2020 | $980,000 | -30.5% | 5,540 | -45.7% | 0.02% | -55.3% |
| Q1 2020 | $1,411,000 | +119.4% | 10,196 | +143.3% | 0.04% | +216.7% |
| Q4 2019 | $643,000 | +512.4% | 4,191 | +478.9% | 0.01% | +500.0% |
| Q3 2019 | $105,000 | -96.7% | 724 | -96.8% | 0.00% | -96.6% |
| Q2 2019 | $3,218,000 | +348.8% | 22,518 | +241.2% | 0.06% | +51.3% |
| Q3 2018 | $717,000 | -86.5% | 6,600 | -87.7% | 0.04% | -85.3% |
| Q2 2018 | $5,300,000 | +387.6% | 53,706 | +383.5% | 0.27% | +315.6% |
| Q1 2018 | $1,087,000 | -68.1% | 11,107 | -69.7% | 0.06% | -64.6% |
| Q4 2017 | $3,403,000 | +695.1% | 36,658 | +634.3% | 0.18% | +654.2% |
| Q3 2017 | $428,000 | -92.4% | 4,992 | -92.6% | 0.02% | -93.4% |
| Q2 2017 | $5,668,000 | +1233.6% | 67,168 | +1252.6% | 0.36% | +1110.0% |
| Q1 2017 | $425,000 | -85.8% | 4,966 | -87.0% | 0.03% | -87.4% |
| Q4 2016 | $2,983,000 | +1566.5% | 38,326 | +1575.1% | 0.24% | +1883.3% |
| Q3 2016 | $179,000 | -42.8% | 2,288 | -26.1% | 0.01% | -33.3% |
| Q2 2016 | $313,000 | -83.5% | 3,098 | -84.5% | 0.02% | -83.3% |
| Q1 2016 | $1,896,000 | +12.1% | 19,991 | +9.8% | 0.11% | +9.1% |
| Q4 2015 | $1,691,000 | -4.4% | 18,201 | -12.3% | 0.10% | +11.2% |
| Q3 2015 | $1,768,000 | -12.9% | 20,744 | -12.5% | 0.09% | -10.1% |
| Q2 2015 | $2,030,000 | -49.9% | 23,718 | -50.3% | 0.10% | -50.0% |
| Q1 2015 | $4,049,000 | +11.7% | 47,686 | +12.8% | 0.20% | +1.0% |
| Q4 2014 | $3,625,000 | +500.2% | 42,288 | +431.8% | 0.20% | +429.7% |
| Q3 2014 | $604,000 | -90.0% | 7,952 | -89.6% | 0.04% | -89.8% |
| Q2 2014 | $6,048,000 | – | 76,816 | – | 0.36% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |